Widal Test Procedure, Principle, and Results

The Widal test procedure helps identify typhoid fever caused by Salmonella enterica serotype Typhi. Developed by Georges Fernand Isidore Widal in the late 19th century, provided insights into antibodies indicative of exposure to the typhoid-causing bacterium.

Typhoid fever, a potentially severe and life-threatening illness, necessitates accurate and timely diagnosis for effective treatment. The Widal test, based on the principles of serological reactions, has been a longstanding method for assessing the immune response of individuals to Salmonella typhi.

Note that some studies propose that the Widal test should not be employed as a standalone diagnostic tool to exclude the presence of typhoid fever. Instead, its use is recommended with invasive clinical assessments and additional confirmatory tests for a more comprehensive and accurate diagnosis.

Widal Test Principle

The Widal test exposes the patient’s serum to killed Salmonella typhi bacteria carrying specific antigens. If the patient has been previously exposed to the bacterium, their immune system would have generated antibodies that specifically bind to these antigens. The ensuing antigen-antibody reactions result in visible clumping or agglutination, forming the basis of the test. The presence or absence of agglutination becomes a crucial indicator of the patient’s immune response to Salmonella typhi.

Types of Antigens Used: “H,” “O,” “AH,” and “BH”:*

The Widal test employs various antigens to assess the immune response comprehensively. The “O” antigen, a somatic antigen, and the “H” antigen, a flagellar antigen derived from Salmonella typhi, are fundamental to the test. Additionally, “AH” and “BH” antigens are utilized in certain test variations. These antigens provide specificity, allowing for the identification of different antibodies in the patient’s serum. The selection of antigens contributes to the accuracy and sensitivity of the Widal test, enabling healthcare professionals to distinguish between various stages of infection and tailor appropriate interventions.

Widal Test Procedure: Slide Test

Qualitative method

1. Arrange six slides with reaction circles systematically and label them appropriately as follows:
   1. Slide 1 – ‘PC’  (Positive control)
   2. Slide 2 – ‘NC’ (Negative control)
   3. Slide 3 – ‘O’
   4. Slide 4 – ‘H’
   5. Slide 5 – ‘AH’
   6. Slide 6 – ‘BH’

2. Apply one drop of the positive control to a designated reaction circle on the slide.

3. In the next circle, pipette one drop of isotonic saline as the negative control.

4. Pipette one drop of the patient’s serum onto the remaining four reaction circles.

5. Add one drop of Widal Test antigen into the first two reaction circles (PC & NC).

6. In the remaining four circles, introduce one drop each of ‘O’, ‘H,’ ‘AH,’ and ‘BH’ antigens.

7. Use separate mixing sticks for each circle to ensure uniform dispersion of contents.

8. Gently rock the slide back and forth and observe for agglutination within one minute.

Semi-Quantitative Method

1. Arrange six slides with reaction circles systematically and label them appropriately as follows:
   1. Slide 1 – ‘PC’  (Positive control)
   2. Slide 2 – ‘NC’ (Negative control)
   3. Slide 3 – 5 ul
   4. Slide 4 – 10 ul
   5. Slide 5 – 20 ul
   6. Slide 6 – 40 ul
   7. Slide 7 – 80 ul

2. Pipette your controls on the first two slides.

3. On the subsequent circles, place 5, 10, 20, 40, and 80 ul of the test sample.

4. Add to each reaction circle the test antigen that demonstrated agglutination.

5. Mix the contents across all the reaction circles using applicator sticks.

6. Gently rock the slide back and forth and observe for macroscopic agglutination within one minute.

Widal Test Procedure: Standard Tube Test Method

1. Label each test tube from 1 to 8, representing the dilution steps. Tube 1 is for the initial serum dilution, and Tubes 2 to 8 are for subsequent dilutions.

2. Pipette 0.1 ml of the patient’s serum into Tube 1, which is the starting point for the dilution series.

3. To Tube 1, add 1.9 ml of normal saline. This achieves a 1:20 dilution (0.1 ml serum + 1.9 ml diluent). Mix Tube 1 thoroughly to ensure uniform dilution.

4. Serial Dilution Steps:

Transfer 1.0 ml from Tube 1 to Tube 2.

Add 1.0 ml of normal saline to Tube 2. Mix thoroughly.

Repeat this process for Tubes 3 to 7, maintaining the 1:2 dilution factor at each step.

5. For Tube 8, add 1.0 ml of normal saline without transferring serum. Tube 8 serves as a control with no serum, representing the endpoint of the dilution series.

6. The dilutions achieved in each tube are as follows:

Tube 1: 1:20

Tube 2: 1:40

Tube 3: 1:80

Tube 4: 1:160

Tube 5: 1:320

Tube 6: 1:640

Tube 7: 1:1280

Tube 8: Control (Saline)

7. Mix each tube thoroughly after dilution to ensure proper dispersion.

8. Apply each diluted serum sample to separate wells of a microtiter plate or use individual test tubes for testing.

9. Add the Salmonella-specific test antigen to each well or tube.

10. Incubate the plate or tubes at 37℃ for 18 hours to allow antigen-antibody complex formation.

11. Use a suitable detection method to identify the endpoint, which is the highest dilution showing a detectable signal.

12. Quantify the antibody concentration based on the dilution factor. For instance, if the endpoint is 1:320, the concentration is 320 times the initial dilution (1:20).

Interpretation of Widal Test Results

The visible agglutination in reaction circles indicates that the patient’s serum harbors antibodies against specific Salmonella typhi antigens. This suggests exposure or an ongoing immune response to the bacterium.

The absence of agglutination suggests a lack of detectable antibodies against the targeted antigens, indicating either no exposure to Salmonella typhi or an insufficient immune response.

Titration Explanation

The titer of the patient’s serum is the highest dilution that exhibits visible agglutination. It is represented as a ratio, such as 1:100 or 1:200, denoting the dilution level at which agglutination occurs.

A higher titer signifies a more robust immune response and may indicate an active infection.

H agglutination often provides clearer and more specific results. It can be precious in the early stages of infection. While O agglutination is significant, its reliability may be influenced by factors such as previous vaccination or exposure to other Salmonella species.

Agglutinins start appearing in the serum by the end of the first week after infection. A sharp rise in agglutinin levels is observed in the second and third weeks. Titers remain steady until the fourth week, after which they may decline.

Understanding the dynamics of agglutination patterns, titration levels, and the comparative reliability of H and O agglutination aids healthcare professionals in drawing meaningful conclusions from Widal test results. It offers a temporal dimension to the immune response, allowing for a more nuanced interpretation and informed decisions regarding patient care and treatment strategies.

Related: Rapid Salmonella Antigen Test: Purpose, Procedure, Principle and Results

Limitations and Challenges

While the Widal test has proven its utility in diagnosing typhoid fever, it is essential to acknowledge its inherent limitations and the challenges associated with its interpretation.

1. The Widal test is time-consuming, particularly in determining antibody titers. By the time results are obtained, valuable time may have elapsed, potentially delaying the initiation of appropriate antibiotic treatment.

2. Interpretation of Widal test results relies on baseline titers within the local population. Variability in baseline titers over time and in different geographical areas can complicate the determination of clinically significant levels of antibodies.

3. Individuals who have previously been vaccinated or exposed to S. Typhi may yield false-positive results due to the presence of residual antibodies.

4. Cross-reactivity with other Salmonella species can occur, leading to inaccurate results.

5. Various conditions, such as chronic liver disease, rheumatoid arthritis, and dysgammaglobulinemia, may contribute to false-positive results.

6. Early Treatment: Early initiation of antibiotic treatment can suppress the rise of antibodies, potentially resulting in false-negative results.

7. Severe hypoproteinaemia may hinder the rise of O and H antibody titres.

Conclusion

Medical technicians have long used the widal test to offer insights into the serological responses of individuals exposed to Salmonella typhi. However, as our understanding of infectious diseases evolves, so does the need for a nuanced diagnostic approach. The Widal test, with its time-consuming nature and susceptibility to various influencing factors, requires careful interpretation and consideration of its limitations.  Recognizing the importance of baseline titers and potential sources of false results, healthcare professionals must navigate these challenges judiciously. 

Embracing modern alternatives, from molecular diagnostics to multiplexed assays, provides a more comprehensive toolkit for accurate and timely diagnosis. A holistic approach, blending traditional wisdom with contemporary advancements, ensures that the pursuit of accurate typhoid fever diagnosis continues to evolve, ultimately enhancing patient outcomes and shaping the future of infectious disease management.